Antengene’s XPOVIO received regulatory approval in Hong Kong for Relapsed and/or Refractory Multiple Myeloma

CAR-T Digest - August 2020

17 Jul 2023: XPOVIO (selinexor) / Relapsed and/or Refractory Multiple Myeloma / Antengene: Received regulatory approval in Hong Kong

HKSAR has approved an NDA for Selinexor + Dexamethasone in Relapsed/Refractory Multiple Myeloma patients who have received at least four prior therapies
XPOVIO is the first and only XPO1 inhibitor approved in Hong Kong
To date, 6 XPOVIO regimens have been included in a total of 27 clinical guidelines from major oncology societies in the US, Europe, and Asia Pacific
- NCCN: 5 regimens for the treatment of myeloma and 1 regimen for the treatment of lymphoma
- CSCO: 4 regimens for the treatment of myeloma and 1 regimen for the treatment of lymphoma
- CACA: 4 regimens for the treatment of myeloma
- ESMO: 2 regimens for the treatment of myeloma
- IMWG: 1 regimen for the treatment of myeloma
“Antengene is very pleased to receive regulatory approval for XPOVIO® in Hong Kong. Despite recent advances in the treatment of R/R MM, there remains an unmet need to extend survival for patients with this life-threatening disease and the approval of XPOVIO® presents Hong Kong patients with access to a novel therapy in their treatment of R/R MM. We will continue to build out Antengene’s presence across APAC markets and strive to expand the indications of XPOVIO® in Hong Kong and the broader APAC region, in efforts to bring renewed hope to more cancer patients.” said Thomas Karalis, Antengene’s Corporate Vice President, Head of Asia Pacific Region